Oct 26, 2020 · Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver transformational therapies for larger populations of patients with cancer

Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline

At Scorpion Therapeutics, we are expanding the reach of precision medicine to more people with untreatable or treatment-resistant cancer.

Oct 13, 2023 · Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations. Read More

A lot of companies try to advertise cross-collaboration. At Scorpion, it’s not only true, but better than I could have imagined.

Scorpion’s Phase 1/2 clinical trial is a multi-center, global, open-label study designed to evaluate the safety and tolerability of STX-478 in multiple ascending doses for patients with locally advanced or metastatic HR+/HER2- breast cancer and other solid tumors driven by …

Scorpion Therapeutics, Inc., a pioneering clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, today announced the closing of a $150 million Series C financing.

Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer

BOSTON, Mass. – November 7, 2022 – Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the formation of its Clinical Scientific Advisory Board (“Clinical SAB”).

%PDF-1.3 %Äåòåë§ó ÐÄÆ 3 0 obj /Filter /FlateDecode /Length 5662 >> stream x ½œÍr GrÇïý íÛÐAŒ¦?g:öD‚”D­)jIÈò†c D‰Ü .@j-¿€o{ð ...